Event JSON
{
"id": "114671e305906d15f3e3fd363449015f1aaeacb3051ae00243d7a22189ddabdf",
"pubkey": "de1abdd3127788ab39fb6f558233067d7cf07e8165598738c9a46a9cff3979a0",
"created_at": 1745566906,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/why-summit-therapeutics-rocketed-double-200500961.html"
],
[
"subject",
"Why Summit Therapeutics Rocketed Double-Digits Today"
],
[
"published_at",
"1745438700"
],
[
"image",
"https://s.yimg.com/ny/api/res/1.2/hHgz.KvXyWSeOvY5iTG.7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/55917c323746a1ac555e10c5bfcba981"
],
[
"p",
"de1abdd3127788ab39fb6f558233067d7cf07e8165598738c9a46a9cff3979a0",
"wss://articles.layer3.news"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://s.yimg.com/ny/api/res/1.2/hHgz.KvXyWSeOvY5iTG.7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/55917c323746a1ac555e10c5bfcba981"
],
[
"t",
"Billy Duberstein"
],
[
"t",
"health"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"The trial showed that ivonescimab delivered a statistically significant improvement in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) compared to the current standard of care, tislelizumab. This news is significant as it could potentially lead to ivonescimab becoming a blockbuster drug, displacing existing standards of care."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nWHY SUMMIT THERAPEUTICS ROCKETED DOUBLE-DIGITS TODAY\n\nhttps://s.yimg.com/ny/api/res/1.2/hHgz.KvXyWSeOvY5iTG.7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MzM-/https://media.zenfs.com/en/motleyfool.com/55917c323746a1ac555e10c5bfcba981\n--\n✍️ Summit Therapeutics' shares surged 14.7% on Wednesday as the company announced positive results from its phase III trial for its lung cancer drug, ivonescimab.\n--\n👉 Summit Therapeutics' shares surged 14.7% on Wednesday\n👉 Positive results from phase III trial for lung cancer drug, ivonescimab\n👉 Ivonescimab delivered a statistically significant improvement in patients with NSCLC\n👉 Could potentially lead to ivonescimab becoming a blockbuster drug\n\n--\n#BillyDuberstein #health\n--\nnostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqm5jd7th84u3jnskts6kqhsh9cdh2ujl0yxtaymcpqzy6gccn48lsm9yxxp \n ",
"sig": "9723b21050e1d1fd6334b141ff533cf51394f97b17eda33a8bb9625ffd2bbadbee7baa376a3cc30668f3687640035c9333e516c05ef8fbbf6accee0cabf1bf6e"
}
